13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

Xenon Pharmaceuticals Inc. XENE

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy.
  • In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
  • The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy.
  • Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE N/A FCF -6.14% Buyback -4.16%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baker Bros. Advisors 0.1% $21.5M 2026-03-31
Duquesne Family Office Stanley Druckenmiller 0.4% $13,875 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 2 Last 4 13F filing periods
Net reducers 0 Last 4 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $21.5M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares New +608,808 / 0
Duquesne Family Office Stanley Druckenmiller 1 filing periods
13F 2026-03-31 Filed 2026-05-15
New Shares - 13F value change +$13,875
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 4 periods +238,600 (New) Total shares 238,600 Value $13,875
Baker Bros. Advisors 4 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$11.7M
13F 2025-06-30 Filed 2025-08-14
Minor increase Shares 6.6% 13F value change -$68,028
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-15
Unchanged Shares 0.0% 13F value change $0
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 4 periods +370,208 (New) Total shares 370,208 Value $21.5M

Recent mentions

No public mentions.